Cullinan Therapeutics, Inc. Segments Disclosure
The Company operates and manages the business as one reporting and one operating segment, which is the business of developing immunology and oncology therapies. Cullinan has determined that its Chief Executive Officer is the chief operating decision maker ("CODM"). Cullinan’s CODM reviews financial information on an aggregate basis and uses net loss attributable to Cullinan as presented in the consolidated statement of operations and comprehensive income (loss) for purposes of allocating resources and evaluating financial performance.
Financial information of the Company’s reportable segment for 2025 and 2024 are as follows (in thousands):
|
|
2025 |
|
|
2024 |
|
||
Research and development ("R&D") programs: |
|
|
|
|
|
|
||
CLN-049 |
|
$ |
17,088 |
|
|
$ |
7,508 |
|
CLN-418 |
|
|
— |
|
|
|
6,471 |
|
CLN-617 |
|
|
6,778 |
|
|
|
4,403 |
|
CLN-619 |
|
|
23,118 |
|
|
|
25,096 |
|
CLN-978 |
|
|
23,074 |
|
|
|
14,833 |
|
Early-stage programs |
|
|
6,286 |
|
|
|
5,938 |
|
Velinotamig |
|
|
1,619 |
|
|
|
— |
|
Zipalertinib |
|
|
33,548 |
|
|
|
31,875 |
|
Total R&D program expense |
|
|
111,511 |
|
|
|
96,124 |
|
Equity-based compensation |
|
|
36,040 |
|
|
|
37,824 |
|
R&D personnel and operations |
|
|
39,986 |
|
|
|
31,532 |
|
General and administrative personnel |
|
|
13,572 |
|
|
|
14,578 |
|
License agreement obligations |
|
|
20,303 |
|
|
|
100 |
|
Other segment expenses(1) |
|
|
20,236 |
|
|
|
16,761 |
|
Loss from operations |
|
|
(241,648 |
) |
|
|
(196,919 |
) |
Other income (expense): |
|
|
|
|
|
|
||
Interest income |
|
|
22,212 |
|
|
|
29,660 |
|
Other income (expense), net |
|
|
(443 |
) |
|
|
(199 |
) |
Net loss before income taxes |
|
|
(219,879 |
) |
|
|
(167,458 |
) |
Income tax expense (benefit) |
|
|
— |
|
|
|
117 |
|
Net loss |
|
|
(219,879 |
) |
|
|
(167,575 |
) |
Net loss attributable to noncontrolling interests |
|
|
— |
|
|
|
(192 |
) |
Net loss attributable to Cullinan |
|
$ |
(219,879 |
) |
|
$ |
(167,383 |
) |
All of the Company’s long-lived assets were located in the U.S. as of each of December 31, 2025 and 2024. Expenditures for additions to long-lived assets included purchases of property and equipment for 2025. There were no expenditures for long-lived assets in 2024.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 10, 2026 | Showing above |
| 2024 | Feb 27, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.